View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 15, 2020

Coronavirus company news summary

By Allie Nawrat

15 April 2020

Moderna has begun enrolment of participants for the highest dose arm of the Phase I clinical trial assessing its mRNA-1273 vaccine candidate against Covid-19. Led by the US National Institutes of Health (NIH), the trial is designed to include arms for 25μg, 100μg and 250μg dose levels of mRNA-1273.

Merck Group subsidiary MilliporeSigma has agreed to support The Jenner Institute in Oxford, UK, in the large-scale manufacturing of the latter’s Covid-19 vaccine candidate, ChAdOx1 nCoV-19. The partners worked together to cut the manufacturing process time from approximately 6-12 months to two months.

NantKwest and ImmunityBio are in discussions with the US Food and Drug Administration (FDA) regarding the development of Covid-19 vaccines and therapeutics. The collaboration combines ImmunityBio’s vaccine development and natural killer cell activation capabilities with NantKwest’s off-the-shelf, cell-based therapeutics expertise. Read the full story here

Clara Health has partnered with Lyft and public relations firm VSC to launch an initiative to enhance Covid-19 participation by matching patients to relevant clinical trials. Clara Health developed a registry platform and database called World Without COVID, which lists more than 300 Covid-19 trials; the database is open for researchers and public.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU